Transient MOG antibody seroconversion associated with immunomodulating therapy
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2020
|
| In: |
Multiple Sclerosis and Related Disorders
Year: 2019, Volume: 37 |
| ISSN: | 2211-0356 |
| DOI: | 10.1016/j.msard.2019.101420 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.msard.2019.101420
|
| Author Notes: | Marc Pawlitzki, Christin Campe, Leoni Rolfes, Hans-Jochen Heinze, Frank Leypoldt, Klaus-Peter Wandinger, Markus Reindl, Brigitte Wildemann, Sven Jarius, Peter Körtvelyessy |
| Item Description: | Gesehen am 04.05.2020 Available online: 28 September 2019 Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 2211-0356 |
| DOI: | 10.1016/j.msard.2019.101420 |